Publication: Infliximab therapy in behcet's uveitis
dc.contributor.author | Alizadegan, F. | |
dc.contributor.buuauthor | Yalçınbayır, O. | |
dc.contributor.buuauthor | Gündüz, G. Uçan | |
dc.contributor.buuauthor | Pehlivan, Y. | |
dc.contributor.buuauthor | PEHLİVAN, YAVUZ | |
dc.contributor.buuauthor | YALÇINBAYIR, ÖZGÜR | |
dc.contributor.orcid | 0000-0002-7311-5277 | |
dc.contributor.orcid | 0000-0002-5458-1686 | |
dc.contributor.researcherid | IYJ-9408-2023 | |
dc.contributor.researcherid | AAH-6661-2021 | |
dc.date.accessioned | 2024-09-12T08:13:06Z | |
dc.date.available | 2024-09-12T08:13:06Z | |
dc.date.issued | 2022-10-20 | |
dc.description.abstract | Purpose. - To evaluate the efficacy of infliximab (IFX) therapy in patients with Behc , et's uveitis (BU) refractory to conventional immunomodulatory treatment (IMT).Materials and methods. - This study, trial registration number TCTR20200806007, included cases of BU with a minimum of 18 months follow-up on IFX treatment. Demographic char-acteristics, ophthalmological examination findings, control of ocular inflammation with IFX, response to treatment and the rate of clinical remission were analyzed in this study.Results. - Sixty-two eyes of 35 patients on IFX therapy were included in the study. The mean follow-up was 49.5 +/- 25.9 months. The mean frequency of recurrences during the IMT was 1.47 +/- 0.78 (attacks/year), decreasing to 0.31 +/- 0.40 (attacks/year) with IFX (P < 0.001). Visual acuity improved significantly in the 1st month of IFX treatment (P = 0.026). Partial response to treatment was achieved in 91.4% of cases.Conclusion. - IFX is a safe and effective treatment in cases of BU refractory to conventional IMT. | |
dc.identifier.doi | 10.1016/j.jfo.2022.04.009 | |
dc.identifier.endpage | 1041 | |
dc.identifier.issn | 0181-5512 | |
dc.identifier.issue | 9 | |
dc.identifier.startpage | 1036 | |
dc.identifier.uri | https://doi.org/10.1016/j.jfo.2022.04.009 | |
dc.identifier.uri | https://hdl.handle.net/11452/44629 | |
dc.identifier.volume | 45 | |
dc.identifier.wos | 000877684400023 | |
dc.indexed.wos | WOS.SCI | |
dc.language.iso | en | |
dc.publisher | Masson Editeur | |
dc.relation.journal | Journal Francais D Ophtalmologie | |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | |
dc.rights | info:eu-repo/semantics/closedAccess | |
dc.subject | Necrosis-factor-alpha | |
dc.subject | Refractory uveoretinitis | |
dc.subject | Follow-up | |
dc.subject | Disease | |
dc.subject | Cytokines | |
dc.subject | Induction | |
dc.subject | Remission | |
dc.subject | Anti tumor necrosis factor | |
dc.subject | Behcet&rsquo | |
dc.subject | S disease | |
dc.subject | Infliximab | |
dc.subject | Noninfectious | |
dc.subject | Uveitis | |
dc.subject | Science & technology | |
dc.subject | Life sciences & biomedicine | |
dc.subject | Ophthalmology | |
dc.title | Infliximab therapy in behcet's uveitis | |
dc.type | Article | |
dspace.entity.type | Publication | |
relation.isAuthorOfPublication | 0075f2ae-ae8a-4690-bd46-128775e8efac | |
relation.isAuthorOfPublication | e21cc14e-0a29-42c8-a7a0-93bd3c780b36 | |
relation.isAuthorOfPublication.latestForDiscovery | 0075f2ae-ae8a-4690-bd46-128775e8efac |